Clinic
Castle Medical Center
Castle Medical Center was paid $37.62M by Medicaid between Jan 2018 and Dec 2024, across 264 billing codes. Its largest line is 99285, emergency room visit (most serious) — 30% of everything it billed.
33Billing provider infoCASTLE MEDICAL CENTER
KAILUA, HI 96734
KAILUA, HI 96734
33aNPI1316937691assigned 10/26/2005
33bProvider typeClinic/Center
28Total paid$37.62M
24GClaims573,202
24DCodes billed264
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Hawaii
Rank by total paid#1 of 41
Median peer was paid$75K
This provider vs. median504×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 83,130 | $6.42M | |
| 2019 | 82,298 | $6.13M | |
| 2020 | 56,635 | $4.12M | |
| 2021 | 75,736 | $4.58M | |
| 2022 | 88,862 | $5.35M | |
| 2023 | 93,346 | $5.20M | |
| 2024incomplete | 93,195 | $5.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30% | 12,833 | 11,256 | $11.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 16,410 | 14,519 | $8.03M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 19,949 | 18,318 | $7.34M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.1% | 3,471 | 3,211 | $3.03M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 5,125 | 4,808 | $1.48M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 1,671 | 1,548 | $927K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.4% | 613 | 555 | $915K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,817 | 5,311 | $374K |
| 80061 | Lipid panel | <1% | 7,314 | 6,892 | $299K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,486 | 3,815 | $263K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,716 | 2,676 | $255K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,269 | 3,540 | $244K |
252 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,235 | $229K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,032 | $223K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,544 | $184K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,404 | $171K |
| 87340 | <1% | 1,226 | $171K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,699 | $137K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,062 | $124K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,222 | $98K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 479 | $90K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,968 | $83K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 79 | $66K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 970 | $64K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,760 | $61K |
| 80076 | <1% | 6,927 | $55K | |
| 80053 | Comprehensive metabolic panel | <1% | 22,180 | $54K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,504 | $50K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,869 | $49K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,257 | $43K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 954 | $42K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 753 | $40K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 967 | $38K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 451 | $37K |
| 99223 | Prolong inpt eval add15 m | <1% | 314 | $37K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 402 | $35K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,108 | $34K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 549 | $33K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,246 | $33K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,177 | $33K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 461 | $32K |
| G0378 | Hospital observation service, per hour | <1% | 483 | $29K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 694 | $29K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 877 | $26K |
| 73562 | <1% | 1,688 | $26K | |
| 86803 | <1% | 1,369 | $25K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 329 | $24K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 85 | $24K |
| 87186 | <1% | 1,868 | $22K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,748 | $22K |
| 73630 | <1% | 2,116 | $20K | |
| 81514 | <1% | 160 | $19K | |
| 0352U | <1% | 207 | $19K | |
| 73610 | <1% | 1,637 | $18K | |
| 73030 | <1% | 1,345 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,399 | $17K |
| 87653 | <1% | 433 | $17K | |
| 76830 | Ultrasound, transvaginal | <1% | 510 | $16K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 177 | $15K |
| 73130 | <1% | 1,386 | $14K | |
| 86850 | <1% | 1,931 | $14K | |
| 83880 | <1% | 2,974 | $14K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 504 | $13K |
| 76770 | <1% | 223 | $11K | |
| 83970 | <1% | 177 | $11K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,183 | $11K |
| 73110 | <1% | 953 | $10K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,444 | $9K |
| 97162 | <1% | 196 | $9K | |
| 88142 | <1% | 1,926 | $9K | |
| 76642 | <1% | 523 | $7K | |
| 72100 | <1% | 351 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,062 | $7K |
| 70486 | <1% | 99 | $7K | |
| 82378 | <1% | 1,187 | $7K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 703 | $6K |
| 97161 | <1% | 129 | $6K | |
| 72110 | <1% | 117 | $5K | |
| 70491 | <1% | 24 | $5K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 203 | $5K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 918 | $5K |
| 84466 | <1% | 518 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,010 | $4K |
| 84702 | <1% | 780 | $4K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 140 | $4K |
| 96367 | <1% | 1,504 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 269 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 54 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,965 | $4K |
| 93017 | <1% | 297 | $4K | |
| 87660 | <1% | 1,787 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 152 | $3K |
| 82728 | <1% | 1,191 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,093 | $3K |
| 87070 | <1% | 1,390 | $2K | |
| 85027 | <1% | 2,384 | $2K | |
| 93016 | <1% | 124 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 44 | $2K |
| 31575 | <1% | 26 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,977 | $2K |
| 90656 | <1% | 95 | $2K | |
| 87077 | <1% | 1,049 | $2K | |
| 86481 | <1% | 39 | $2K | |
| 87631 | <1% | 337 | $2K | |
| 73140 | <1% | 234 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 450 | $2K |
| 90715 | <1% | 1,322 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,087 | $2K |
| 93018 | <1% | 124 | $1K | |
| 71250 | <1% | 13 | $1K | |
| 85610 | <1% | 4,745 | $1K | |
| J3490 | Unclassified drugs | <1% | 10,711 | $1K |
| 84484 | <1% | 9,051 | $1K | |
| 82570 | <1% | 789 | $1K | |
| 81001 | <1% | 11,231 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 41 | $1K |
| 86787 | <1% | 173 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,644 | $1K |
| 73502 | <1% | 86 | $1K | |
| 76536 | <1% | 27 | $1K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 339 | $1K |
| 82950 | <1% | 793 | $1K | |
| 82043 | <1% | 1,614 | $1K | |
| 73080 | <1% | 126 | $1K | |
| 87040 | <1% | 3,978 | $976.51 | |
| 84403 | <1% | 61 | $940.45 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $874.53 |
| 73564 | <1% | 18 | $830.67 | |
| 72050 | <1% | 12 | $789.82 | |
| 94729 | <1% | 24 | $769.40 | |
| 86038 | <1% | 12 | $742.81 | |
| 87205 | <1% | 490 | $735.99 | |
| 83001 | <1% | 26 | $714.41 | |
| 82550 | <1% | 2,695 | $708.54 | |
| 93971 | <1% | 50 | $704.67 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 84 | $661.88 |
| 36415 | Collection of venous blood by venipuncture | <1% | 40,255 | $657.51 |
| 87088 | <1% | 1,789 | $647.35 | |
| 87150 | <1% | 12 | $634.58 | |
| 87481 | <1% | 41 | $632.33 | |
| 76801 | <1% | 13 | $614.57 | |
| 82803 | <1% | 1,882 | $584.44 | |
| 82607 | <1% | 791 | $582.38 | |
| 83605 | <1% | 4,213 | $579.83 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $563.95 |
| 84703 | <1% | 2,243 | $542.51 | |
| 86900 | <1% | 2,252 | $501.70 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,089 | $489.97 |
| 86706 | <1% | 16 | $475.03 | |
| 93000 | <1% | 86 | $464.26 | |
| C1769 | Guide wire | <1% | 211 | $459.30 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,972 | $420.98 |
| 83735 | <1% | 7,701 | $417.05 | |
| 84153 | <1% | 27 | $405.67 | |
| 82274 | <1% | 57 | $395.28 | |
| 81025 | <1% | 4,161 | $349.50 | |
| 83690 | <1% | 7,753 | $327.85 | |
| 87480 | <1% | 12 | $319.05 | |
| 81003 | <1% | 3,656 | $318.30 | |
| 73590 | <1% | 54 | $267.26 | |
| 85379 | <1% | 1,153 | $256.80 | |
| 82746 | <1% | 26 | $254.72 | |
| 71101 | <1% | 30 | $248.60 | |
| 86592 | <1% | 1,059 | $238.47 | |
| 84550 | <1% | 1,316 | $221.17 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 29 | $219.22 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,564 | $201.05 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 45 | $193.45 |
| 86780 | <1% | 667 | $164.66 | |
| 83540 | <1% | 1,369 | $161.30 | |
| 80179 | <1% | 15 | $151.45 | |
| 93246 | <1% | 13 | $147.78 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 464 | $133.65 |
| 93880 | <1% | 13 | $105.64 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,652 | $100.00 |
| 87210 | <1% | 63 | $97.66 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,379 | $97.10 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,444 | $96.67 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,777 | $93.83 |
| 73090 | <1% | 60 | $90.18 | |
| 85651 | <1% | 1,252 | $88.25 | |
| 88304 | <1% | 13 | $75.44 | |
| 83718 | <1% | 13 | $70.58 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 248 | $70.49 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,134 | $69.47 |
| 85014 | <1% | 690 | $65.80 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,180 | $47.78 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,114 | $46.46 |
| 85730 | <1% | 3,331 | $42.54 | |
| 82962 | <1% | 1,710 | $30.22 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 956 | $28.23 |
| 80143 | <1% | 16 | $27.30 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 186 | $25.39 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,985 | $23.95 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 243 | $22.99 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 177 | $22.80 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,639 | $17.04 |
| 84100 | <1% | 1,480 | $16.40 | |
| 82948 | <1% | 1,846 | $15.34 | |
| 86762 | <1% | 524 | $14.68 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,184 | $13.73 |
| 84439 | <1% | 2,731 | $13.69 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,869 | $13.42 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 113 | $10.46 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 14 | $9.18 |
| 85007 | <1% | 1,633 | $8.94 | |
| 86901 | <1% | 2,254 | $7.58 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,102 | $7.43 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 870 | $5.52 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 89 | $5.37 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 325 | $5.14 |
| 86140 | <1% | 1,450 | $4.63 | |
| 81002 | <1% | 72 | $3.54 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 891 | $0.98 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 262 | $0.08 |
| 1159F | <1% | 3,645 | $0.01 | |
| 1160F | 0% | 2,213 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 68 | $0.00 |
| 84156 | 0% | 465 | $0.00 | |
| 84450 | 0% | 15 | $0.00 | |
| 82465 | 0% | 13 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 197 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 236 | $0.00 |
| 3078F | 0% | 80 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
| 97116 | 0% | 22 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 63 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 139 | $0.00 |
| 94664 | 0% | 108 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 93 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 22 | $0.00 |
| 87400 | 0% | 80 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 44 | $0.00 |
| 99152 | 0% | 141 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 66 | $0.00 |
| 82248 | 0% | 14 | $0.00 | |
| 94726 | 0% | 12 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 1,572 | $0.00 |
| 96376 | 0% | 2,351 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 2,234 | $0.00 |
| 3008F | 0% | 992 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 99 | $0.00 |
| 51798 | 0% | 173 | $0.00 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 314 | $0.00 |
| 83550 | 0% | 401 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 121 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 66 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 62 | $0.00 |
| 83615 | 0% | 52 | $0.00 | |
| 12001 | 0% | 81 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 95 | $0.00 |
| 12002 | 0% | 25 | $0.00 | |
| 87510 | 0% | 12 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 40 | $0.00 |
| 85018 | 0% | 291 | $0.00 | |
| 97035 | 0% | 121 | $0.00 | |
| 3074F | 0% | 88 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 16 | $0.00 |
| 86317 | 0% | 12 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 16 | $0.00 |
| 96127 | 0% | 13 | $0.00 | |
| 3079F | 0% | 30 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 29 | $0.00 |
| 84132 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, NICOLAS (FINANCE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Castle Medical Center | Kailua, HI | $629K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.